Loading
Every dated change on the records linked to Locally advanced cervical cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Durvalumab added to chemoradiotherapy did not significantly improve progression-free survival in locally advanced cervical cancer.
5-year OS 80% vs 72% (HR 0.
PFS HR 0.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
5-year OS 72% vs 71%; no benefit.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.